{
    "clinical_study": {
        "@rank": "138030", 
        "acronym": "Maestro", 
        "arm_group": [
            {
                "arm_group_label": "Mirabegron", 
                "arm_group_type": "Active Comparator", 
                "description": "1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 md daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or , for those in the placebo arm, two placebo tablets."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 md daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or , for those in the placebo arm, two placebo tablets."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if the study drug, Mirabegron, is safe and effective in\n      treating symptoms of Overactive Bladder in people with Parkinson's Disease."
        }, 
        "brief_title": "A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Parkinsons Disease", 
        "condition_browse": {
            "mesh_term": [
                "Parkinson Disease", 
                "Urinary Bladder, Overactive"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is a randomized 1:1 placebo-controlled 10-week study of Mirabegron as add-on\n      therapy to an educational intervention of behavioral modification including pelvic floor\n      exercise (PFE) in a cohort of 40 Parkinson's subjects over the age of 30 with overactive\n      bladder (OAB).   Active drug will be Mirabegron 25 mg daily with up-titration to 50 mg daily\n      after 5 weeks.  Subjects will be enrolled based on response to an overactive bladder\n      questionnaire at visit 2.\n\n      Enrolled subjects will have 4 study visits to the clinic as well as 2 phone visits.\n\n      Enrolled subjects will be asked to record urinary symptoms and pelvic floor exercises in a\n      diary at 3 separate time points for a 72 hour period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:-\n\n          -  Diagnosis of Parkinsons by United Kingdom brain bank criteria\n\n          -  Age > 30 years old\n\n          -  No change in Parkinsons medications during the 4 weeks preceding screening, with no\n             dose changes during the study, except that PRN (as needed) doses of\n             carbidopa/levodopa will be allowed to address periodic worsening of parkinsonian\n             symptoms.\n\n          -  Patient willing and able to complete micturition diary\n\n          -  Urinary urgency (\u2265 8 entries of bladder urgency score > 2) in 72hr voiding diary\n             during screening period\n\n          -  Micturition frequency \u2265 8 / 24hr or incontinence \u2265 2 episodes in 72hr voiding diary\n             during screening period\n\n          -  Use of other medication that could influence bladder function, other than those\n             specifically prohibited (see below), will be permitted as long as the dose is stable\n             for 4 weeks preceding screening, with no dose changes during the study.\n\n          -  Patient expects to have valid health insurance for the duration of the study period\n\n        Exclusion Criteria:\n\n          -  Women who are breast-feeding, pregnant or have potential to become pregnant during\n             the course of the study (fertile and unwilling/unable to use effective contraceptive\n             measures).\n\n          -  Cognitive deficits that in the opinion of the investigator would interfere with the\n             subject's ability to give informed consent or perform study testing.\n\n          -  Screening blood pressure > 165 systolic or 100 diastolic\n\n          -  Heart rate > 100\n\n          -  History of allergy to Mirabegron.\n\n          -  Screening post-void residual > 200ml\n\n          -  Evidence of urinary tract infection at screening\n\n          -  History of chronic inflammation such as interstitial cystitis, bladder stones,\n             previous pelvic radiation therapy, or previous or current malignant disease of the\n             pelvic organs\n\n          -  Intravesical botulinum toxin treatment within the previous six months of screening.\n\n          -  Presence of Interstim device\n\n          -  Use of indwelling catheter or self-catheterization\n\n          -  Concurrent use of thioridazine, flecainide, propafenone, or Digoxin\n\n          -  Concurrent use of warfarin (Coumadin)\n\n          -  Use of one of the anti-cholinergic bladder medications specified below within 14 days\n             of the screening visit. Subjects who have used one of these medications in the past\n             but discontinued it at least 14 days prior to the screening visit can be enrolled.\n\n          -  Screening estimated glomerular filtration rate (eGFR) < 60, AST ( aspartate\n             aminotransferase )  or ALT ( alanine aminotransferase ) > 2x upper limit of normal\n\n          -  Any other serious and/or unstable medical condition\n\n          -  Participation in other drug studies or use of other investigational drugs within 30\n             days prior to Screening Visit."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02092181", 
            "org_study_id": "DBPA-2013-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Mirabegron", 
                    "Placebo"
                ], 
                "description": "25 mg po daily for 32-40 days. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.", 
                "intervention_name": "Mirabegron", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Mirabegron", 
                    "Placebo"
                ], 
                "description": "Placebo 25 mg po daily.  Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "contact": {
                "email": "clgonzales@evergreenhealth.com", 
                "last_name": "Carey L Gonzales, Coordinator", 
                "phone": "425-899-5374"
            }, 
            "contact_backup": {
                "email": "sekilcup@evergreenhealth.com", 
                "last_name": "Shalom E Kilcup, Coordinator", 
                "phone": "425-899-5369"
            }, 
            "facility": {
                "address": {
                    "city": "Kirkland", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98034"
                }, 
                "name": "Evergreenhealth Booth Gardner Parkinsons Care Center"
            }, 
            "investigator": [
                {
                    "last_name": "Daniel J Burdick, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Pinky Agarwal, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease. (MAESTRO)", 
        "other_outcome": [
            {
                "description": "Change in mean daily OAB-SCS, Visit 3 vs. baseline", 
                "measure": "Secondary Outcome Measures based on Voiding Diary", 
                "safety_issue": "No", 
                "time_frame": "baseline (7-14 days post visit 1) and visit 3 (32-40 days post visit 2)"
            }, 
            {
                "description": "Mean number of micturitions per 24 hours, Visit 3 and Visit 4 vs. baseline", 
                "measure": "Secondary Outcome Measures based on Voiding Diary", 
                "safety_issue": "No", 
                "time_frame": "baseline (7-14 days post visit 1), visit 3 (32-40 days post visit 2) and visit 4 (74-82 days post visit 2)"
            }, 
            {
                "description": "Mean number of incontinence episodes per 24 hours, Visit 3 and Visit 4  vs. baseline", 
                "measure": "Secondary Outcome Measures based on Voiding Diary", 
                "safety_issue": "No", 
                "time_frame": "baseline (7-14 days post visit 1) visit 3 (32-40 days post visit 2) and visit 4 (74-82 days post visit 2)"
            }, 
            {
                "description": "Mean Volume voided per micturition", 
                "measure": "Secondary Outcome Measures based on Voiding Diary", 
                "safety_issue": "No", 
                "time_frame": "baseline (7-14 dayspost visit 1) visit 3 (32-40 days post visit 2) and visit 4 (74-82 days post visit 2)"
            }
        ], 
        "overall_contact": {
            "email": "clgonzales@evergreenhealth.com", 
            "last_name": "Carey L Gonzales, Coordinator", 
            "phone": "425-899-5374"
        }, 
        "overall_contact_backup": {
            "email": "sekilcup@evergreenhealth.com", 
            "last_name": "Shalom Kilcup, Coordinator", 
            "phone": "425-899-5369"
        }, 
        "overall_official": [
            {
                "affiliation": "Evergreen Health", 
                "last_name": "Daniel J Burdick, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Evergreen Health", 
                "last_name": "Pinky Agarwal, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome measure will be the change in the mean daily Overactive Bladder-Symptom Composite Score (OAB-SCS) from baseline (visit 2)  to visit 4.\nThe Over active Bladder- Symptom Composite Score requires subjects to record the severity of urgency of each micturition over a 72 hour period.", 
            "measure": "Change in the mean daily Overactive Bladder-Symptom Composite Score.", 
            "safety_issue": "No", 
            "time_frame": "7-82 days. From visit 2 (baseline) to visit 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02092181"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Burdick, Daniel, M.D.", 
            "investigator_full_name": "Daniel Burdick, MD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Overactive Bladder questionnaire symptom severity scale (OAB-q), Visit 3 and Visit 4 vs. baseline", 
                "measure": "Secondary Outcome Measures based on clinic visits", 
                "safety_issue": "No", 
                "time_frame": "baseline (7-14 days post visit 1), visit 3( 32-40 days post visit 2) and visit 4(74-82 days post visit 2)"
            }, 
            {
                "description": "Non-Motor Symptoms Scale (NMSS), which includes questions about cognition, psychosis, and constipation, in addition to urinary symptoms; Visit 3 and Visit 4 vs. baseline.", 
                "measure": "Secondary Outcome Measures based on clinic visits", 
                "safety_issue": "No", 
                "time_frame": "baseline (7-14 days post visit 1), visit 3 (32-40 days post visit 2)  and visit 4 (74-82 days post visit 2)"
            }, 
            {
                "description": "PDQ-8, a measure of global quality of life, Visit 3 and Visit 4 vs. baseline", 
                "measure": "Secondary Outcome Measures based on clinic visits", 
                "safety_issue": "No", 
                "time_frame": "baseline ( 7-14 days post visit 1), visit 3 (32-40 days post visit 2) and visit 4 (74-82 days post visit 2)"
            }, 
            {
                "description": "Patient Perception of Bladder Condition at Visit 3 and Visit 4 vs. baseline", 
                "measure": "Secondary Outcome Measures based on clinic visits", 
                "safety_issue": "No", 
                "time_frame": "baseline (7-14 days post visit 1), visit 3 (32-40 days post visit 2) and visit 4 (74-82 days post visit 2)"
            }, 
            {
                "description": "Subject's Global Impression of Change at Visit 3 and Visit 4 vs. baseline", 
                "measure": "Secondary Outcome Measures based on clinic visits", 
                "safety_issue": "No", 
                "time_frame": "baseline (7-14 days post visit 1), visit 3 (32-40 days post visit 2) and visit 4 (74-82 days post visit 2)"
            }
        ], 
        "source": "Burdick, Daniel, M.D.", 
        "sponsors": {
            "collaborator": {
                "agency": "Astellas Pharma US, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Daniel Burdick, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}